Evaluation of sofosbuvir plus daclatasvir combination for hepatitis C virus treatment

被引:0
作者
Moron Romero, Rocio [1 ]
Diaz, Xando [1 ]
del Carmen Gonzalez, Maria [1 ]
Rodriguez, Alejandro [1 ]
Casas, Inmaculada [1 ]
Cabeza, Jose [1 ]
机构
[1] Complejo Hosp Univ Granada, Pharm, Granada, Spain
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
PT028
引用
收藏
页码:331 / 331
页数:1
相关论文
共 50 条
[41]   Post-transplant Treatment of Severe Recurrent Hepatitis C (HCV) with Daclatasvir and Sofosbuvir Plus or Minus Ribavirin [J].
Bzowej, Natalie H. ;
Joshi, Shobha ;
Therapondos, George ;
Girgrah, Nigel ;
Tyson, Gia ;
Goldvarg-Abud, Inna ;
Scheuermann, Jennifer B. ;
Bohorquez, Humberto E. ;
Cohen, Ari J. ;
Carmody, Ian C. ;
Reichman, Trevor W. ;
Bruce, David S. ;
Loss, George E. .
HEPATOLOGY, 2014, 60 :542A-543A
[42]   Successful treatment with sofosbuvir and daclatasvir plus ribavirin in acute hepatitis C-infected patient with hepatic decompensation [J].
Wu, Sih-Hsien ;
Chao, Chi-Jen ;
Huang, Yi-Hsiang ;
Hou, Ming-Chih .
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2019, 82 (07) :595-598
[43]   Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3 [J].
Belperio, Pamela S. ;
Shahoumian, Troy A. ;
Loomis, Timothy P. ;
Mole, Larry A. ;
Backus, Lisa I. .
JOURNAL OF HEPATOLOGY, 2019, 70 (01) :15-23
[44]   Sofosbuvir plus daclatasvir for hepatitis C virus-cryoglobulinemia vasculitis (HCV-CryoVas): VASCUVALDIC 2 Study [J].
Saadoun, D. ;
Pol, S. ;
Ferfar, Y. ;
Hezode, C. ;
Ahmed, S. N. S. ;
Alric, L. ;
de Saint Martin, L. ;
Bouyer, A. S. ;
Musset, L. ;
Poynard, T. ;
Rigon, M. R. ;
Cacoub, P. .
JOURNAL OF HEPATOLOGY, 2017, 66 (01) :S56-S57
[45]   Effect of Sofosbuvir Plus Daclatasvir in Hepatitis C Virus Genotype-4 Patients: Promising Effect on Liver Fibrosis [J].
Abdel-Aziz, Asmaa M. ;
Ibrahim, Mohamed A. ;
El-Sheikh, Azza A. ;
Kamel, Maha Y. ;
Zenhom, Nagwa M. ;
Abdel-Raheim, Salam ;
Abdelhaleem, Hisham .
JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2018, 8 (01) :15-22
[46]   Cognitive assessment in patients with Hepatitis C submitted to treatment with Sofosbuvir and Simeprevir or Daclatasvir [J].
Polo Gascon, Maria Rita ;
Guerra Benute, Glaucia Rosana ;
Macedo, Elizeu Coutinho ;
Capitao, Claudio Garcia ;
Vidal, Jose Ernesto ;
Smid, Jerusa ;
Nascimento Marcusso, Rosa Maria ;
Souza de Lucia, Mara Cristina ;
Penalva-de-Oliveira, Augusto Cesar ;
Diament, Decio .
ARQUIVOS DE NEURO-PSIQUIATRIA, 2020, 78 (06) :342-348
[47]   Sofosbuvir treatment and hepatitis C virus infection [J].
Nakamura, Masato ;
Kanda, Tatsuo ;
Haga, Yuki ;
Sasaki, Reina ;
Wu, Shuang ;
Nakamoto, Shingo ;
Yasui, Shin ;
Arai, Makoto ;
Imazeki, Fumio ;
Yokosuka, Osamu .
WORLD JOURNAL OF HEPATOLOGY, 2016, 8 (03) :183-190
[48]   Efficacy and safety of a fixed dose combination tablet of asunaprevir plus beclabuvir plus daclatasvir for the treatment of Hepatitis C [J].
Zappulo, Emanuela ;
Scotto, Riccardo ;
Buonomo, Antonio Riccardo ;
Maraolo, Alberto Enrico ;
Pinchera, Biagio ;
Gentile, Ivan .
EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (03) :261-273
[49]   Sofosbuvir for the treatment of hepatitis C virus infection [J].
Rolland, Sebastien ;
Vachon, Marie-Louise .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2015, 187 (03) :203-204
[50]   Sofosbuvir treatment and hepatitis C virus infection [J].
Masato Nakamura ;
Tatsuo Kanda ;
Yuki Haga ;
Reina Sasaki ;
Shuang Wu ;
Shingo Nakamoto ;
Shin Yasui ;
Makoto Arai ;
Fumio Imazeki ;
Osamu Yokosuka .
World Journal of Hepatology, 2016, (03) :183-190